GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with Down syndrome; implications for leukemogenesis

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 7, 2005, Pages 408-409

  Hellebostad, Marit ^a   Carpenter, Emily ^b   Hasle, Henrik ^c   Mitchell, Chris ^b   Vyas, Paresh ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 1;

CANCER RISK; CASE REPORT; CHILD; DOWN SYNDROME; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; LETTER; LEUKEMIA; LEUKEMOGENESIS; PRIORITY JOURNAL;

BONE MARROW CELLS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DOWN SYNDROME; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; FEMALE; GATA1 TRANSCRIPTION FACTOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MUTATION; TRANSCRIPTION FACTORS;

EID: 23044487167     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000172223.04694.c4     Document Type: Letter

References (13)

1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169.
2. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004; 103:399-406.
3. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5:11-20.
4. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
5. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-986.
6. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480-2489.
7. Shivdasani RA, Fujiwara Y, McDevitt MA, et al. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16:3965-3973.
8. Vyas P, Ault K, Jackson CW, et al. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93:2867-2875.
9. Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005 [Epub ahead of print]
10. Li Z, Godinho FJ, Klusmann JH, et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613-619.
11. Kuhl C, Atzberger A, Nieswandt B, et al. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. (Submitted for publication).
12. Warner JK, Wang JC, Hope KJ, et al. Concepts of human leukemic development. Oncogene. 2004;23:7164-7177.
13. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311-321.